New York, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the human papillomavirus market is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies and healthcare spending globally. DelveInsight’s Human Papillomavirus Market Insights report includes a comprehensive understanding of current treatment practices, human papillomavirus emerging drugs, market share of individual therapies, and current and forecasted human papillomavirus market size from 2020 to 2034, segmented into 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Human Papillomavirus Market Report According to DelveInsight’s analysis, the market size of HPV in the 7MM is expected to grow at a significant CAGR by 2034. Our analysis reveals HPV is significantly more prevalent in males than females, highlighting a crucial gender disparity in its occurrence. Prominent companies working in the domain of HPV, including Inovio Pharmaceuticals, Inc.
, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Barinthus Biotherapeutics, pHion Therapeutics, Vir Biotechnology, Inc., Antiva Biosciences, Toragen, Inc., Precigen, Inc, Merck Sharp & Dohme LLC, ViMREX GmbH , and others, are actively working on innovative drugs for HPV.
These novel HPV the.
